(Reuters) -The U.S. Food and Drug Administration has approved Verastem’s combination therapy for patients with a type of ovarian cancer who have received prior treatment, the regulator said on Thursday.
The FDA approved the combination under the brand name, Avmapki Fakzynja Co-pack, for adult patients with a mutated form of the gene known as KRAS.
KRAS-mutated recurrent low-grade serous ovarian cancer is a type of cancer that arises after initial treatment for the disease caused by a mutation in the KRAS gene.
Verastem did not immediately respond to a Reuters request for comment.
Share of the company were halted in mid-day trading.
(Reporting by Sriparna Roy and Padmanabhan Ananthan in Bengaluru; Editing by Leroy Leo)
